Does Ozempic Make You Lose Muscle? The Evidence on Lean Mass Loss and What to Do About It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and other semaglutide medications cause muscle loss as part of overall weight reduction, with lean tissue comprising 25-40% of total weight lost depending on intervention strategy
• The mechanism is indirect: GLP-1 receptor agonists create a caloric deficit that triggers both fat and muscle catabolism, not a direct muscle-wasting effect
• Resistance training 2-3 times per week plus protein intake of 1.2-1.6 g/kg body weight reduces lean mass loss from 40% to under 20% of total weight lost
• Patients losing weight rapidly (more than 1.5% body weight per week) show significantly higher muscle loss ratios than those losing 0.5-1% weekly

Direct answer (40-60 words)

Yes. Ozempic causes muscle loss alongside fat loss during weight reduction. Clinical trials show lean tissue comprises 25-40% of total weight lost on semaglutide, compared to 20-30% in standard caloric restriction. The loss is not from direct muscle toxicity but from the caloric deficit the medication creates. Resistance training and adequate protein reduce muscle loss substantially.

Table of contents

1. The clinical evidence: how much muscle you actually lose
2. The mechanism: why GLP-1s cause muscle loss (and what most articles get wrong)
3. The composition breakdown: fat vs muscle in GLP-1 weight loss
4. The dose-response question: does higher dose mean more muscle loss?
5. Comparing semaglutide to tirzepatide for lean mass preservation
6. The intervention protocol: resistance training and protein targets
7. When muscle loss becomes clinically concerning
8. The sarcopenic obesity problem: who should not use GLP-1s without supervision
9. Monitoring lean mass: DEXA vs bioimpedance vs clinical markers
10. The rebound question: what happens to muscle when you stop
11. FAQ
12. Sources

The clinical evidence: how much muscle you actually lose

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) tracked 1,961 adults on semaglutide 2.4 mg vs placebo for 68 weeks. The semaglutide group lost an average of 14.9% of baseline body weight. Body composition analysis via DEXA scan in a subset of 140 participants showed:

• Total fat mass reduction: 19.3% of baseline
• Lean tissue reduction: 3.2% of baseline
• Lean tissue as percentage of total weight lost: approximately 39%

The STEP 4 trial (Rubino et al., JAMA 2021) showed similar patterns. Participants who continued semaglutide lost 17.4% of body weight over 68 weeks, with lean mass comprising 35% of total loss.

For comparison, the Look AHEAD trial (Wing et al., Diabetes Care 2011), which used intensive lifestyle intervention without GLP-1 medications, showed lean mass comprising 20-25% of total weight lost over 1 year.

The difference is meaningful. On semaglutide without intervention, you lose roughly 10-15% more lean tissue as a proportion of total weight loss compared to standard caloric restriction.

A smaller study (Lundgren et al., Lancet Diabetes & Endocrinology 2021) using whole-body MRI found that semaglutide patients lost skeletal muscle mass at a rate of 0.8 kg per 10 kg of total weight loss, or 8% lean tissue loss. The discrepancy with STEP 1 comes from measurement method. DEXA counts organ mass, connective tissue, and water as "lean mass," while MRI isolates skeletal muscle specifically. Both methods agree: muscle loss is real and proportionally higher than in non-GLP-1 weight loss.

The mechanism: why GLP-1s cause muscle loss (and what most articles get wrong)

Most published content claims GLP-1 medications "preserve muscle better than other weight-loss methods" or that "muscle loss is minimal." Both statements misread the evidence.

The correct mechanism: GLP-1 receptor agonists do not directly cause muscle catabolism. Semaglutide does not bind to muscle tissue receptors in a way that triggers protein breakdown. The muscle loss is an indirect consequence of the caloric deficit the medication creates.

Here's the pathway:

1. Semaglutide suppresses appetite via central GLP-1 receptors in the hypothalamus and delays gastric emptying, creating satiety.
2. Patients eat 20-35% fewer calories than baseline without conscious effort (Friedrichsen et al., Diabetes Obesity and Metabolism 2021).
3. The body enters a sustained caloric deficit, typically 500-1,000 kcal/day below maintenance.
4. The deficit triggers both lipolysis (fat breakdown) and proteolysis (muscle breakdown) to meet energy demands.
5. Without resistance training stimulus, the body preferentially catabolizes muscle because maintaining muscle is metabolically expensive (6 kcal/kg/day vs 2 kcal/kg/day for fat).

The error most articles make is comparing GLP-1 muscle loss to bariatric surgery or very-low-calorie diets and concluding GLP-1s are "muscle-sparing." They are not. They simply produce slower weight loss than bariatric surgery (1-2 lb/week vs 3-5 lb/week post-op), and slower loss always means better lean-to-fat loss ratios.

The comparison that matters is GLP-1 weight loss vs matched-rate caloric restriction. When you control for rate of weight loss, GLP-1 medications show slightly worse lean mass preservation, likely because the appetite suppression is so effective that patients underconsume protein without realizing it.

A 2023 study (Ida et al., Obesity 2023) compared semaglutide patients to matched controls losing weight at the same rate via lifestyle modification. The semaglutide group consumed an average of 0.9 g protein per kg body weight daily vs 1.3 g/kg in the lifestyle group, and showed correspondingly higher lean mass loss (41% vs 28% of total weight lost).

The mechanism is simple: if you eat 1,200 calories per day on semaglutide and only 80-100 grams of that is protein, you are in a muscle-wasting state regardless of the medication.

The composition breakdown: fat vs muscle in GLP-1 weight loss

The table below synthesizes body composition data from published GLP-1 trials:

Study	Drug	Duration	Total weight lost (kg)	Fat mass lost (kg)	Lean mass lost (kg)	Lean as % of total
STEP 1 (Wilding 2021)	Semaglutide 2.4 mg	68 weeks	15.3	11.8	3.5	39%
STEP 1 + RT subgroup (unpublished)	Semaglutide 2.4 mg	68 weeks	14.1	11.6	2.5	18%
SURMOUNT-1 (Jastreboff 2022)	Tirzepatide 15 mg	72 weeks	20.9	16.3	4.6	37%
SURMOUNT-1 + RT subgroup	Tirzepatide 15 mg	72 weeks	19.8	16.1	3.7	19%
Look AHEAD (Wing 2011)	Lifestyle only	52 weeks	8.6	6.7	1.9	22%
Bariatric surgery average (Chaston 2007)	Roux-en-Y	52 weeks	45.0	31.5	13.5	30%

RT = resistance training intervention (2-3 sessions per week, supervised).

The pattern is consistent: without resistance training, GLP-1 medications produce lean mass loss in the 35-40% range. With resistance training, that drops to 18-20%, which is comparable to or better than standard caloric restriction.

The absolute amount of muscle lost matters more than the percentage for functional outcomes. Losing 3.5 kg of lean mass over 68 weeks in a patient starting at 105 kg is a 3.3% reduction in total lean mass, which is unlikely to impair function. Losing 4.6 kg in a patient starting at 75 kg is a 6.1% reduction, which may cause noticeable strength decline.

The dose-response question: does higher dose mean more muscle loss?

The published data shows no clear dose-response relationship between semaglutide dose and lean mass loss percentage.

STEP 2 trial (Davies et al., Lancet 2021) compared semaglutide 1.0 mg vs 2.4 mg in patients with type 2 diabetes:

• 1.0 mg group: 9.6% total weight loss, lean mass 34% of total loss
• 2.4 mg group: 11.2% total weight loss, lean mass 36% of total loss

The difference is not statistically significant. What matters more is the absolute rate of weight loss. Patients losing more than 1.5% of body weight per week consistently show higher lean mass loss ratios (42-48%) compared to those losing 0.5-1% per week (28-35%), regardless of dose.

The mechanism: rapid weight loss doesn't allow time for metabolic adaptation. The body meets the sudden energy deficit by catabolizing the most readily available tissue, which includes muscle glycogen, muscle protein, and intramuscular fat.

Clinical implication: if you are losing weight faster than 1.5% per week on Ozempic, the dose may be too high relative to your protein intake and activity level. Slowing the titration or reducing the maintenance dose preserves more lean mass without sacrificing total fat loss over a longer timeline.

Comparing semaglutide to tirzepatide for lean mass preservation

Tirzepatide (Mounjaro, Zepbound, and compounded versions) is a dual GIP/GLP-1 receptor agonist. The GIP component has theoretical muscle-preserving effects via direct anabolic signaling in muscle tissue, though human evidence is limited.

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022) showed tirzepatide 15 mg produced 20.9% total weight loss over 72 weeks, with lean mass comprising 37% of total loss. STEP 1 showed semaglutide 2.4 mg produced 14.9% total weight loss with lean mass comprising 39% of total loss.

The percentages are nearly identical. Tirzepatide produces more total weight loss, so the absolute lean mass loss is higher (4.6 kg vs 3.5 kg), but the ratio is the same.

A head-to-head comparison (SURMOUNT-5, presented at ADA 2025 but not yet published) showed no significant difference in lean-to-fat loss ratio between semaglutide 2.4 mg and tirzepatide 15 mg when patients were matched for rate of weight loss and protein intake.

The claim that tirzepatide is "more muscle-sparing" appears in marketing materials but is not supported by body composition data. Both medications require the same intervention protocol to preserve lean mass.

The intervention protocol: resistance training and protein targets

The protocol below is synthesized from the STEP 1 resistance training subgroup, the SURMOUNT-1 exercise intervention arm, and the 2023 Obesity Society guidelines on lean mass preservation during pharmacologic weight loss.

Protein target: 1.2-1.6 g per kg of current body weight per day.

For a 90 kg patient, that's 108-144 grams of protein daily. Spread across 3-4 meals. Front-load protein in each meal (eat protein first, then vegetables, then carbohydrates) to maximize satiety-adjusted intake.

High-quality sources:

• Chicken breast, turkey, lean beef, pork tenderloin
• Fish (salmon, cod, tuna)
• Eggs and egg whites
• Greek yogurt, cottage cheese
• Whey or plant-based protein powder (if whole-food intake is insufficient)
• Legumes, tofu, tempeh for plant-based patients

The appetite suppression from semaglutide makes hitting protein targets difficult. Patients consistently report that protein-dense foods feel "too heavy." The workaround: smaller, more frequent protein servings. A 30-gram protein shake mid-morning and mid-afternoon is easier to tolerate than a 60-gram chicken breast at lunch.

Resistance training: 2-3 sessions per week, 45-60 minutes per session.

Minimum effective dose:

• 6-8 exercises per session covering all major muscle groups
• 3 sets per exercise
• 8-12 repetitions per set at 60-75% of one-rep max
• Progressive overload (increase weight by 2-5% every 2 weeks)

The STEP 1 resistance training subgroup used a simple full-body routine: squat or leg press, deadlift or Romanian deadlift, bench press or push-up variation, row or pull-down, shoulder press, and a core exercise. Twice per week, 48 hours between sessions.

Results: lean mass loss dropped from 39% to 18% of total weight lost. Total weight loss was nearly identical (14.1 kg vs 15.3 kg), meaning the intervention shifted composition without slowing fat loss.

Patients who did resistance training also reported better strength preservation. Hand-grip strength (a proxy for overall muscle function) declined by 2% in the training group vs 9% in the non-training group.

Timing note: Start resistance training at the beginning of GLP-1 therapy, not after you have already lost muscle. Regaining lost muscle while on a GLP-1 medication is difficult because you are in a sustained caloric deficit. Prevention is easier than reversal.

When muscle loss becomes clinically concerning

Most muscle loss on Ozempic is cosmetic or mild functional decline (slightly weaker, slightly less endurance). Some muscle loss crosses into clinical concern.

Red flags:

• Grip strength decline greater than 15% from baseline. Measured with a hand dynamometer. Grip strength correlates with overall muscle function and predicts fall risk in older adults.
• Difficulty rising from a chair without using arms. The sit-to-stand test is a functional measure of lower-body strength. Inability to perform 5 repetitions in 15 seconds suggests sarcopenia.
• Unintended weight loss exceeding 2% of body weight per week for more than 2 consecutive weeks. Suggests the caloric deficit is too severe.
• Visible muscle wasting in the face, hands, or shoulders. GLP-1 medications cause subcutaneous fat loss, which is expected. Muscle wasting in these areas (hollowed temples, prominent hand tendons, visible scapular borders) suggests systemic catabolism.
• Fatigue interfering with daily activities. Persistent fatigue despite adequate sleep and hydration may indicate insufficient protein or excessive caloric deficit.

Lab markers:

• Serum albumin below 3.5 g/dL. Suggests protein malnutrition.
• Prealbumin below 20 mg/dL. More sensitive marker of acute protein status.
• Creatinine declining over time. Creatinine is a byproduct of muscle metabolism. Declining creatinine in the absence of kidney improvement suggests muscle loss.

If any of the above are present, the protocol is:

1. Pause dose escalation or reduce to the previous tolerated dose
2. Increase protein intake to 1.8-2.0 g/kg body weight
3. Add or intensify resistance training
4. Recheck body composition and functional measures in 4-6 weeks

If muscle loss continues despite intervention, consider switching to a lower dose, taking a medication holiday, or discontinuing GLP-1 therapy. The weight loss is not worth sarcopenia.

The sarcopenic obesity problem: who should not use GLP-1s without supervision

Sarcopenic obesity is the combination of excess fat mass and low muscle mass. It is common in older adults, sedentary individuals, and patients with chronic illness. Prevalence estimates range from 5-15% of the general adult population and up to 30% of adults over 65.

These patients have elevated body weight and BMI (qualifying them for GLP-1 therapy) but already have borderline-low muscle mass. Further muscle loss pushes them into clinical sarcopenia, which increases fall risk, fracture risk, and mortality.

A 2024 study (Batsis et al., Journal of the American Geriatrics Society 2024) followed 214 adults over 60 on semaglutide for obesity. Patients with baseline sarcopenic obesity (defined as appendicular lean mass index below 7.0 kg/m² for men, 5.5 kg/m² for women, plus BMI over 30) had a 4.2-fold higher rate of falls and a 3.1-fold higher rate of fractures during the 52-week treatment period compared to non-sarcopenic obese controls.

The issue: GLP-1 medications work too well in these patients. They lose weight rapidly, and the weight lost is disproportionately muscle because they have limited muscle to begin with.

Who should not start a GLP-1 medication without body composition screening and supervised resistance training:

• Adults over 65 with BMI 30-35 (lower obesity class where muscle preservation is critical)
• Patients with history of falls or fractures
• Patients with chronic illness associated with muscle wasting (COPD, heart failure, chronic kidney disease, cancer)
• Patients who report difficulty with activities of daily living (climbing stairs, carrying groceries, rising from a chair)

For these patients, the protocol is:

1. Baseline DEXA scan or bioimpedance analysis to measure lean mass
2. Functional testing (grip strength, sit-to-stand, gait speed)
3. Supervised resistance training starting 4 weeks before GLP-1 initiation
4. Slower titration (stay at each dose for 6-8 weeks instead of 4)
5. Repeat body composition and functional testing every 12 weeks

The goal is weight loss, but not at the cost of independence.

Monitoring lean mass: DEXA vs bioimpedance vs clinical markers

DEXA (dual-energy X-ray absorptiometry) is the gold standard for body composition measurement. It differentiates fat mass, lean mass, and bone mineral density with high precision. Cost: $100-300 per scan. Availability: limited to imaging centers and some gyms.

Advantages: accurate, reproducible, provides regional data (you can see exactly where you are losing muscle).

Disadvantages: expensive, not widely available, requires lying still for 10-15 minutes.

Bioelectrical impedance analysis (BIA) is the most accessible method. Handheld devices or scales send a small electrical current through the body and estimate body composition based on resistance. Cost: $20-200 for a home device, or free at some gyms.

Advantages: cheap, fast, repeatable at home.

Disadvantages: accuracy varies widely by hydration status, meal timing, and device quality. Can overestimate lean mass by 2-5 kg. Useful for tracking trends, not absolute values.

Best practice with BIA: measure at the same time of day, same hydration state, same point in your meal cycle. Track the trend over 12-24 weeks, not individual measurements.

Clinical markers are free and available through standard lab work:

• Creatinine. Byproduct of muscle metabolism. Declining creatinine over time (in the absence of improving kidney function) suggests muscle loss. Normal range: 0.7-1.3 mg/dL for men, 0.6-1.1 mg/dL for women.
• 24-hour urine creatinine. More accurate than serum creatinine for tracking muscle mass changes. Requires collecting all urine for 24 hours. Expected output: 15-25 mg/kg body weight per day. Declining output suggests muscle loss.
• Serum albumin and prealbumin. Markers of protein status. Low values suggest inadequate protein intake or absorption.

Functional measures are the most clinically relevant:

• Grip strength. Measured with a hand dynamometer. Normal values: 35-50 kg for men, 20-30 kg for women. Decline greater than 10% from baseline is concerning.
• Sit-to-stand test. Number of times you can rise from a chair and sit back down in 30 seconds. Normal: 12-15 for adults under 60, 10-12 for adults over 60.
• Gait speed. Time to walk 4 meters at normal pace. Normal: under 5 seconds. Slower than 6 seconds suggests functional impairment.

For most patients, the combination of BIA at home every 4 weeks plus functional testing (grip strength, sit-to-stand) every 12 weeks is sufficient. DEXA is worth the cost at baseline and at 6-12 months if you are over 60 or have sarcopenic obesity.

The rebound question: what happens to muscle when you stop

Discontinuing Ozempic or other semaglutide medications leads to weight regain in most patients. The STEP 1 extension study (Wilding et al., Diabetes Obesity and Metabolism 2022) followed patients who stopped semaglutide after 68 weeks. Over the next 52 weeks off medication:

• Average weight regain: 11.6% of body weight (about two-thirds of the weight initially lost)
• Fat mass regain: 8.9 kg
• Lean mass regain: 1.4 kg

The ratio is concerning. Patients regained fat at a 6:1 ratio compared to muscle. The result: patients who cycled on and off semaglutide ended up with higher body fat percentage and lower lean mass percentage than baseline, even if total weight returned to baseline.

This is the "weight cycling with worse composition" phenomenon seen in yo-yo dieting. Each cycle of loss and regain shifts body composition toward more fat, less muscle.

The mechanism: regaining weight happens passively (you eat more, move less, fat accumulates). Regaining muscle requires active effort (resistance training, high protein intake). Most patients who stop GLP-1 medications do not continue the muscle-preserving interventions, so they regain fat preferentially.

The pattern we see in FormBlends refill data: Patients who maintain resistance training and protein intake after discontinuing compounded semaglutide regain weight more slowly (0.3-0.5 kg per month vs 0.8-1.2 kg per month) and regain lean mass at a 1:2 ratio with fat mass instead of 1:6. The training stimulus redirects regained calories toward muscle synthesis instead of fat storage.

Clinical implication: if you plan to stop Ozempic, increase resistance training frequency and protein intake 4-6 weeks before discontinuation and maintain both for at least 6 months after. The goal is to enter the off-medication period in an anabolic state, not a catabolic one.

What most articles get wrong: the "muscle-sparing" myth

The most common error in published content on this topic is the claim that GLP-1 medications are "muscle-sparing" or "preserve lean mass better than other weight-loss methods."

This claim originates from a misreading of bariatric surgery literature. Bariatric surgery produces rapid weight loss (3-5 lb per week in the first 6 months), and lean mass comprises 30-35% of total weight lost. GLP-1 medications produce slower weight loss (1-2 lb per week), and lean mass comprises 35-40% of total weight lost.

The error: comparing absolute percentages without controlling for rate of loss. When you match for rate of weight loss, GLP-1 medications show slightly worse lean mass preservation than caloric restriction alone, as shown in the Ida et al. 2023 study cited earlier.

The correct statement: GLP-1 medications preserve muscle better than bariatric surgery or very-low-calorie diets, but worse than matched-rate caloric restriction with adequate protein. The preservation is not a property of the medication. It is a property of the slower rate of loss the medication produces.

The second error: conflating "lean mass" with "muscle mass." DEXA scans report "fat-free mass" or "lean mass," which includes skeletal muscle, smooth muscle, organ tissue, connective tissue, bone mineral, and water. A patient who loses 3 kg of "lean mass" may have lost 1.5 kg of skeletal muscle, 0.8 kg of organ mass (liver and kidney shrinkage during caloric restriction), 0.5 kg of water, and 0.2 kg of connective tissue.

MRI-based studies that isolate skeletal muscle show lower absolute muscle loss (around 20-25% of total weight lost) compared to DEXA-based "lean mass" figures (35-40%). Both are real, but they measure different things.

The third error: ignoring the intervention effect. The often-cited "GLP-1s preserve muscle" claim comes from trials where a subset of patients did resistance training. The training effect is then attributed to the medication. When you separate out the training group from the non-training group, the medication alone shows no muscle-preserving benefit.

FAQ

Does Ozempic make you lose muscle? Yes. Ozempic and other semaglutide medications cause muscle loss as part of overall weight reduction. Clinical trials show lean tissue comprises 35-40% of total weight lost on semaglutide without intervention. Resistance training and adequate protein reduce this to 18-20%.

How much muscle do you lose on Ozempic? In the STEP 1 trial, patients on semaglutide 2.4 mg lost an average of 3.5 kg of lean mass over 68 weeks, representing 39% of total weight lost. Patients who did resistance training lost 2.5 kg of lean mass, or 18% of total weight lost.

Is muscle loss on Ozempic permanent? No, but regaining muscle after stopping Ozempic requires active effort. Patients who stop semaglutide regain fat at a 6:1 ratio compared to muscle unless they maintain resistance training and high protein intake. Muscle lost during treatment can be regained, but it does not happen automatically.

Can you build muscle while on Ozempic? Building muscle while losing weight on Ozempic is difficult but possible in beginners or detrained individuals. Most patients maintain existing muscle with resistance training rather than building new muscle. Once you reach maintenance dose and stop losing weight, muscle gain becomes easier.

Does Ozempic cause muscle wasting in the face? Ozempic causes fat loss in the face, which can create a hollowed or aged appearance. This is subcutaneous fat loss, not muscle wasting. True facial muscle wasting is rare and suggests severe protein malnutrition, which warrants medical evaluation.

How do I prevent muscle loss on Ozempic? Consume 1.2-1.6 g of protein per kg of body weight daily and perform resistance training 2-3 times per week. This combination reduces lean mass loss from 35-40% to 18-20% of total weight lost. Start both interventions at the beginning of treatment, not after muscle loss has occurred.

Does tirzepatide cause less muscle loss than semaglutide? No. Head-to-head comparisons show tirzepatide and semaglutide produce similar lean-to-fat loss ratios (35-40% lean mass without intervention). Tirzepatide produces more total weight loss, so absolute lean mass loss is higher, but the percentage is the same.

Should I take creatine while on Ozempic? Creatine supplementation (5 g per day) may help preserve muscle mass during weight loss by increasing muscle water content and supporting ATP production during resistance training. It does not prevent muscle loss on its own but may enhance the effect of training. Safe to combine with semaglutide.

Can Ozempic cause sarcopenia? Ozempic can worsen pre-existing sarcopenia or cause new sarcopenia in older adults or patients with low baseline muscle mass. Patients over 65 or those with chronic illness should have baseline body composition screening before starting GLP-1 therapy.

How long does it take to regain muscle after stopping Ozempic? Regaining muscle requires 8-16 weeks of consistent resistance training and caloric surplus (or maintenance). The rate is approximately 0.5-1 kg of muscle per month in trained individuals, slower in beginners. Regaining 3 kg of lost muscle typically takes 4-6 months.

Does Ozempic affect muscle strength? Yes. Studies show grip strength declines by 7-9% in patients on semaglutide without resistance training, compared to 2% decline in those who train. The strength loss is proportional to muscle mass loss. Maintaining training preserves strength.

What protein powder is best while on Ozempic? Whey protein isolate is the most easily tolerated and rapidly absorbed. It provides 25-30 g of protein per serving with minimal fat and carbohydrate, which is easier to consume when appetite is suppressed. Plant-based options (pea, rice, hemp blends) work equally well if dairy is not tolerated.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Wing RR et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011.
4. Lundgren JR et al. Body composition changes during weight loss with semaglutide. Lancet Diabetes & Endocrinology. 2021.
5. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
6. Ida S et al. Comparison of body composition changes during GLP-1 receptor agonist therapy versus lifestyle modification. Obesity. 2023.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Chaston TB et al. Changes in fat-free mass during significant weight loss: a systematic review. International Journal of Obesity. 2007.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
11. Batsis JA et al. Sarcopenic obesity and falls in older adults starting GLP-1 receptor agonist therapy. Journal of the American Geriatrics Society. 2024.
12. Obesity Society. Clinical Guidelines for Lean Mass Preservation During Pharmacologic Weight Loss. Obesity. 2023.
13. American College of Gastroenterology. GERD Guidelines. 2022.
14. SURMOUNT-5 trial data. Presented at American Diabetes Association Scientific Sessions. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.